A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
| Hematology |
 ANARGYROS XENCOSTAS, MD, FRCPC, Associate Professor
Dr. Anargyros Xenocostas is currently a Consultant in the Division of Hematology, Department of Medicine, at the London Health Sciences Centre, as well as an Assistant Professor of Medicine at the University of Western Ontario. He also holds a Cross Appointment as an Honourary Consultant in Hematology/Oncology at the London Regional Cancer Centre. Dr. Xenocostas obtained his Bachelor of Science in Honours Immunology and spent several years doing graduate studies at McGill University. The focus of these studies was the mechanisms responsible for the depression of primary B lymphocyte genesis in the bone marrow and subsequent immunosuppression during Graft versus Host reactions. He then went on to obtain his medical degree and complete his studies in Internal Medicine at McGill University. Dr. Xenocostas completed his Hematology Fellowship at the University of Toronto and pursued further subspecialty training in allogeneic bone marrow transplantation at the Princess Margaret Hospital. Current full-time clinical work includes the treatment of patients with hematologic malignancies and hemopoietic stem cell transplantation. Recent research projects have included looking at the effects of anemia during allogeneic hemopoietic stem cell transplantation and the creation of an Acute Myeloid Leukemia Cell Bank. A longstanding research interest has been the potential application of erythropoietin (EPO) as a neuroprotective and cardioprotective agent in collaboration with a number of basic researchers at UWO. Specific research projects have included examination of EPO-mediated effects on delayed vasospasm and the maintenance of cerebral blood flow after subarachnoid hemorrhage, the prevention of deleterious cardiac remodeling after acute myocardial infarction and the effects of anemia and transfusion during acute myocardial infarction. As well, the role of EPO in inflammation and maintenance of normal microcirculation are being examined in septic and hemorrhagic animal models. A number of potential clinical applications for EPO are being explored in Phase I/II trials Keywords: Erythropoietin Hemopoietic stem cell transplantation Leukemia (Acute) Tissue protection Translational research |
